68ga-dotanoc and Melanoma

68ga-dotanoc has been researched along with Melanoma* in 1 studies

Other Studies

1 other study(ies) available for 68ga-dotanoc and Melanoma

Article	Year
Metastatic melanoma to the thyroid gland expressing somatostatin receptors-imaging with 68Ga-DOTANOC PET/CT. Clinical nuclear medicine, 2015, Volume: 40, Issue:2 Malignant melanoma is an aggressive tumor with poor prognosis that can have widespread metastases at presentation. Melanoma is known to undergo neuroendocrine differentiation. We report a case of a 60-year-old woman with malignant melanoma showing a metastatic lesion in the thyroid expressing somatostatin receptors as evident by Ga-DOTANOC PET/CT and metabolically active widespread subcutaneous metastases on F-FDG PET/CT imaging. Topics: Female; Humans; Melanoma; Middle Aged; Multimodal Imaging; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Thyroid Neoplasms; Tomography, X-Ray Computed	2015

Article

Year

Metastatic melanoma to the thyroid gland expressing somatostatin receptors-imaging with 68Ga-DOTANOC PET/CT.

Clinical nuclear medicine, 2015, Volume: 40, Issue:2

Malignant melanoma is an aggressive tumor with poor prognosis that can have widespread metastases at presentation. Melanoma is known to undergo neuroendocrine differentiation. We report a case of a 60-year-old woman with malignant melanoma showing a metastatic lesion in the thyroid expressing somatostatin receptors as evident by Ga-DOTANOC PET/CT and metabolically active widespread subcutaneous metastases on F-FDG PET/CT imaging.

Topics: Female; Humans; Melanoma; Middle Aged; Multimodal Imaging; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Thyroid Neoplasms; Tomography, X-Ray Computed

2015